Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests

By LabMedica International staff writers
Posted on 19 Jan 2026

Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications. More...

Early diagnosis is critical but remains difficult in low-resource settings where laboratory capacity and specialist care are limited. Most diagnoses are still made after symptoms appear, when risks to mothers and babies are already high. Now, an artificial intelligence (AI)-based approach could predict these conditions earlier using data from routine blood tests.

Siemens Healthineers (Erlangen, Germany), with funding support from Gates Foundation (Seattle, WA, USA), has undertaken a project that focuses on applying machine learning to complete blood count (CBC) data combined with basic patient metadata. The goal is to reduce diagnostic burden while enabling earlier, more accurate risk stratification during pregnancy.

Machine learning models will analyze routinely collected CBC parameters alongside relevant clinical information such as ferritin levels. These inputs will be used to generate an integrated maternal health score that flags early risk of pre-eclampsia and identifies anemia. Because CBC tests are already part of standard prenatal care worldwide, the approach does not require additional testing or new laboratory infrastructure.

The project will develop and validate algorithms in collaboration with partners in the Global South, ensuring suitability for low-resource healthcare environments. Pre-eclampsia alone causes more than 76,000 maternal deaths and over 500,000 perinatal deaths annually, with the highest burden in low- and middle-income countries. Anemia affects hundreds of millions of women and children globally and is both preventable and treatable if detected early.

If successful, the AI-derived maternal health score could support frontline clinicians in identifying high-risk pregnancies earlier and prioritizing timely interventions. The approach could help shift care from reacting to severe symptoms toward proactive risk management using existing data. Siemens plans to publish results on algorithm validity and real-world clinical performance at the conclusion of the project.

“Healthcare AI will greatly contribute to predicting outcomes rather than just reacting to symptoms,” said Siemens Healthineers CEO Bernd Montag. “I am excited about this effort to make early diagnosis not just a possibility, but a scalable standard for women and children everywhere.”

Related Links:
Siemens Healthineers
Gates Foundation


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.